Last update: May 13, 2018
Not risky for breastfeeding or infant.
A non-steroidal anti-inflammatory indicated in the treatment of fever, pains, rheumatoid arthritis and other rheumatic complaints.
Oral, intravenous and topical administration (cutaneous or vaginal), every 6 to 8 hours.
Its pharmacokinetic data (high percentage of protein binding, acidic character and short half-life) explain the tiny or zero transfer of milk observed (Rigourd 2014, Walter 1997, Townsend 1984, Albert 1984, Weibert 1982).
No problems have been observed in infants whose mothers were taking it (Walter 1997, Ito 1993, Weibert 1982).
A medication commonly used in pediatrics. Its use is authorized from 6 months of age. The dose that an infant can receive through breastmilk is hundreds of times inferior to the therapeutic dose given to an infant (Rigourd 2014, Walter 1997).
American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001).
List of essential WHO medications: compatible with breastfeeding (WHO/UNICEF, 2002).
Expert authors and medical associations consider it compatible with breastfeeding (Reece 2017, Bordini 2016, Noviani 2016, Davanzo 2014, Sachs 2013, Worthington 2013, Hutchinson 2013, Rowe 2013, Amir 2011, Chen 2010, Risser 2009, Østensen 2007, Spigset 2000 , Janssen 200, Nice 2000, Mitchell 1999, Goldsmith 1989, Needs 1985).
It is regarded as the analgesic of choice for breastfeeding mothers (Worthington 2013, Østensen 2007, Nice 2000).
We do not have alternatives for 2-(4-Isobutylphenyl)propionic acid since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.